Legal Representation
Attorney
John Pickeril
USPTO Deadlines
Next Deadline
37 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2019-09-03)
Due Date
September 03, 2025
Grace Period Ends
March 03, 2026
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
19 eventsDate | Code | Type | Description | Documents |
---|---|---|---|---|
Sep 3, 2024 | REM1 | E | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | Loading... |
Sep 3, 2019 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
Jun 18, 2019 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
Jun 18, 2019 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
May 29, 2019 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
May 10, 2019 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
May 8, 2019 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
May 8, 2019 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
May 6, 2019 | ALIE | A | ASSIGNED TO LIE | Loading... |
Apr 26, 2019 | ERSI | I | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | Loading... |
Apr 26, 2019 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
Nov 8, 2018 | CNSI | R | SUSPENSION INQUIRY WRITTEN | Loading... |
Nov 8, 2018 | GNSI | S | INQUIRY TO SUSPENSION E-MAILED | Loading... |
Nov 8, 2018 | GNS2 | O | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | Loading... |
May 8, 2018 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | Loading... |
May 8, 2018 | GNSL | F | LETTER OF SUSPENSION E-MAILED | Loading... |
May 8, 2018 | CNSL | R | SUSPENSION LETTER WRITTEN | Loading... |
May 7, 2018 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Feb 3, 2018 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
Detailed Classifications
Class 005
Diagnostic agents, preparations and substances for medical and surgical purposes; Diagnostic agents, preparations and substances for medical purposes, namely, the enhancing of adenomatous, cancerous and other proliferative lesions in the colon for patients undergoing colonoscopy and for the visualization of colonic adenoma in patients undergoing screening colonoscopy including patients at high risk of colorectal carcinoma (CRC), including those with previous history of polyps at prior colonoscopy, patients with colorectal cancer and patients with family history; Diagnostic reagents and contrast media for medical and surgical use; Contrast media for use with imaging medical equipment; Contrast media for use with colonoscopic equipment; pharmaceutical preparations for use in gastroenterology; pharmaceutical preparations for use in colonoscopy; pharmaceutical preparations for the differentiation of the tissues of the intestines and colon and lesions thereto; pharmaceutical preparations for use in the colonoscopic diagnostic evaluation; methylene blue for pharmaceutical, medical, surgical and medical diagnostic purposes; dye for pharmaceutical, medical, surgical and medical diagnostic purposes; pharmaceutical preparations for use in the endoscopic diagnostic evaluation; pharmaceutical compositions for use in endoscopy; methylene blue for enhancing visualization during colonoscopy; dyes for enhancing visualization during colonoscopy
Classification
International Classes
005